These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 6107332)
41. [Iatrogenic extrapyramidal disorders]. Ludin HP Schweiz Med Wochenschr; 1990 Jun; 120(23):855-8. PubMed ID: 1972812 [TBL] [Abstract][Full Text] [Related]
42. GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions. Scheel-Krüger J Adv Neurol; 1984; 40():85-90. PubMed ID: 6141713 [No Abstract] [Full Text] [Related]
43. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders. Mondrup K; Dupont E; Braendgaard H Acta Neurol Scand; 1985 Sep; 72(3):341-3. PubMed ID: 3864333 [TBL] [Abstract][Full Text] [Related]
44. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei. Wolfarth S Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834 [No Abstract] [Full Text] [Related]
47. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Dose M; Lange HW Pharmacopsychiatry; 2000 Jan; 33(1):19-27. PubMed ID: 10721880 [TBL] [Abstract][Full Text] [Related]
48. Another view of calcium and extrapyramidal side effects. Bailie GR; Nelson MV; Lesar T Am J Psychiatry; 1983 Nov; 140(11):1537-8. PubMed ID: 6137965 [No Abstract] [Full Text] [Related]
49. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches. May PR; Lee MA; Bacon RC Clin Neuropharmacol; 1983; 6 Suppl 1():S35-51. PubMed ID: 6139165 [No Abstract] [Full Text] [Related]
50. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Grace AA Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673 [TBL] [Abstract][Full Text] [Related]
51. Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties? Laduron PM; Leysen JE J Pharm Pharmacol; 1978 Feb; 30(2):120-2. PubMed ID: 24098 [No Abstract] [Full Text] [Related]
52. Movement disorders with neuroleptic drug treatment. Tarsy D Psychiatr Clin North Am; 1984 Sep; 7(3):453-71. PubMed ID: 6148742 [TBL] [Abstract][Full Text] [Related]
53. L-Dopa and the treatment of extrapyramidal disease. Pelton EW; Chase TN Adv Pharmacol Chemother; 1975; 13():253-304. PubMed ID: 1106161 [No Abstract] [Full Text] [Related]
54. Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain. Johnson AE; Liminga U; Lidén A; Lindefors N; Gunne LM; Wiesel FA Neuroscience; 1994 Dec; 63(4):1003-20. PubMed ID: 7535390 [TBL] [Abstract][Full Text] [Related]
55. Abuse potential of anticholinergics. Dose M; Tempel HD Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():43-6. PubMed ID: 11072764 [TBL] [Abstract][Full Text] [Related]
56. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Glass M; Dragunow M; Faull RL Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533 [TBL] [Abstract][Full Text] [Related]